JCJacques Cohen

Jacques Cohen

*This is an algorithmically generated author record based on publicly available information.

Jacques Cohen has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Automation of sperm preparation, oocyte retrieval and denudation, ICSI, and vitrification in IVF: insights from a proof-of-concept study

    by A Chavez-Badiola, A Valadez Aguilar, G Mendizabal-Ruiz, A Flores-Saiffe Farías, E Hernández-Morales, A Álvarez Lopez, D J Sánchez-González, N Costa-Borges, A Murray, M Alikani, et al.

    STUDY QUESTION: Can key embryological procedures, including sperm preparation, oocyte retrieval and denudation, ICSI, and blastocyst vitrification, be automated? SUMMARY ANSWER: Individual automated systems enabling sperm preparation, oocyte retrieval and denudation, ICSI, and embryo vitrification demonstrated feasibility in a small proof-of-concept study. WHAT IS KNOWN ALREADY: Automated systems for specific IVF procedures have shown promise, with recent reports of successful births following automated gamete isolation and ICSI. STUDY DESIGN, SIZE, DURATION: Prospective proof-of-concept study evaluating five automated systems nicknamed ‘Pearls’. Each system automated one of the following procedures: sperm preparation via swim-up (Pearl 1-SU); sperm preparation by a dish-based approach called horizontal swim-out (Pearl 1-HSO), oocyte retrieval, and denudation (Pearl 2); sperm selection and laser immobilization and piezo-ICSI (Pearl 3); and blastocyst vitrification (Pearl 5). The study enrolled patients undergoing treatment at Hope IVF, Guadalajara, Mexico, between October 2023 and October 2024, with data collection on pregnancy outcomes being completed in October 2025. PARTICIPANTS/MATERIALS, SETTING, METHODS: Thirty-two patients or oocyte donors each underwent a single egg retrieval following minimal or mild ovarian stimulation. One patient was excluded from the study due to poor ovarian response. Oocytes were prospectively allocated to treatment with a single automated system: Pearl 1-SU (n = 20), Pearl 1-HSO (n = 37), Pearl 2 (n = 34), Pearl 3 (n = 57), with sibling oocytes treated manually per standard protocol. In the case of the automated vitrification system (Pearl 5), sibling blastocysts produced following manual ICSI were assigned to either manual or automated (n = 10) vitrification. MAIN RESULTS AND THE ROLE OF CHANCE: Pearl 1-SU and Pearl 1-HSO automated sperm preparation systems achieved fertilization rates of 90% (18/20) and 73% (27/37), and sibling oocytes injected with manually prepared sperm achieved 60% (6/10) and 75% (18/24) fertilization. Usable blastocyst rates were 55.5% (10/18) and 70.4% (19/27) for the automated systems, and 50% (3/6) and 66.7% (12/18) for manual preparation. Pearl 2 automated oocyte retrieval and denudation resulted in a fertilization rate of 79.4% (27/34) and a usable blastocyst rate of 48.1% (13/27); manual procedures achieved 66.7% (26/39) and 76.9% (20/26) fertilization and blastocyst formation rates, respectively. Pearl 3 automated ICSI resulted in a fertilization rate of 59.6% (34/57), while this rate in sibling oocytes injected manually was 80% (36/45). Usable blastocyst formation rates were 58.8% (20/34) for automated and 61.1% (22/36) for manual ICSI. Thirty-five single embryo transfers from the automation group resulted in 16 clinical pregnancies and 16 live births in 26 patients (Pearl 1-SU = 3/6; Pearl 1-HSO = 4/7; Pearl 2 = 4/7; Pearl 3 = 4/13; Pearl 5 = 1/2). Two extremely preterm deliveries in the Pearl 1 group, associated with severe pre-eclampsia and vaginal/urinary infection, respectively, led to neonatal and infant deaths. No transfers involved embryos from the manual group for Pearl 1. One embryo transfer from the manual group of Pearl 2 resulted in a negative pregnancy. In the Pearl 3 manual group, four single blastocyst transfers in four patients resulted in four live births; in the Pearl 5 manual control group, three transfers in three patients resulted in two negative pregnancy results and one early pregnancy loss. LIMITATIONS, REASONS FOR CAUTION: The small sample size and pilot design of this study do not allow statistical comparisons between sibling oocytes from automated and manual treatment groups. The automated systems did not achieve complete autonomy, and several tasks required direct operator intervention or execution through digital control. Pearl 5 encountered technical limitations that require further development before additional clinical evaluation. Although the two extremely preterm births that led to neonatal and infant deaths occurred in the context of clear obstetric complications, they compel collection and analysis of extensive technical and biological data from the automated systems in future studies and close monitoring of all pregnancies and births resulting from these novel procedures. WIDER IMPLICATIONS OF THE FINDINGS: These results show the feasibility of integrating individual automated systems into an IVF laboratory as experimental standalone tools, allowing a stepwise evaluation. The modular approach, once shown to be efficacious, may provide a practical pathway toward broader laboratory automation and enable laboratories to address specific bottlenecks and standardize operations. FUNDING: The study was sponsored by Conceivable Life Sciences, New York, NY, USA. DISCLOSURES: A.C.-B. is an employee, shareholder, and company officer at Conceivable Life Sciences and a shareholder in IVF 2.0 and Hope IVF Mexico. A.V.A. has no conflicts of interest to declare. G.M.-R. is a stock option holder in Conceivable Life Sciences and has received consulting fees from Conceivable Life Sciences and IVF 2.0. A.F.-S.F. is an employee and stock option holder at Conceivable Life Sciences. E.H.-M. is an employee and stock option holder at Conceivable Life Sciences. A.Á.L. is an employee and stock option holder at Conceivable Life Sciences. D.J.S.-G. has no conflicts of interest to declare. N.C.-B. is a stock option holder in Conceivable Life Sciences and has received consulting fees from the company; he is also an employee, shareholder, and company officer at Embryotools. A.M. is a shareholder and company officer at Conceivable Life Sciences and holds shares in TMRW Life Sciences. M.A. is a stock option holder at Conceivable Life Sciences and has received consulting fees and travel support from the company; she has also received consulting fees from TMRW Life Sciences. G.S. is an employee and...

  • Open Access

    Automation and autonomy in the IVF laboratory: concepts and implications for embryologists

    by Jacques Cohen, Gerardo Mendizabal-Ruiz, Giles Anthony Palmer, Giuseppe Silvestri, Mina Alikani

  • Open Access

    Automated oocyte retrieval, denudation, sperm preparation, and ICSI in the IVF laboratory: a proof-of-concept study and report of the first live births

    by A Chavez-Badiola, G Mendizabal-Ruiz, A Flores-Saiffe Farías, N Costa-Borges, A Murray, M Alikani, G Silvestri, C Millan, E Hernández-Morales, R Valencia-Murillo, et al.

    STUDY QUESTION: Can multiple automated systems sequentially perform Day 0 IVF procedures: (i) sperm preparation, (ii) cumulus–oocyte complex (COC) retrieval and oocyte denudation, and (iii) ICSI? SUMMARY ANSWER: Automated sequential Day 0 procedures achieved fertilization in 64.3% of injected oocytes and 42.2% usable blastocyst formation in 11 cases, resulting in five healthy live births from nine patients with positive pregnancy tests. WHAT IS KNOWN ALREADY: The Day 0 procedures—sperm preparation, oocyte handling (e.g. finding and denudation), and ICSI—rely on embryologist skill. Automation in IVF laboratories has the potential to improve reproducibility, yet its implementation remains limited. Fully automated pipetting workflows replicating embryologist activities have not yet been achieved, though partial automation of key steps such as dish preparation and ICSI has been reported. STUDY DESIGN, SIZE, DURATION: Proof-of-concept pilot study with prospective allocation of sibling oocytes to automated or manual protocols. Here, we report on Day 0 automation in 11 cases using two or three automated systems (nicknamed ‘pearls’) in sequence. Single vitrified/warmed blastocyst transfers occurred between April and October 2024. This work was part of a larger research programme evaluating automation across multiple IVF laboratory procedures from gamete handling through blastocyst transfer and specifically demonstrates sequential automation across multiple Day 0 procedures within a single workflow. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eleven consenting patients (three autologous, eight donor egg cycles) underwent IVF/ICSI following minimal or mild stimulation. The gametes were processed using either automated or manual protocols. The automated systems—Pearl 1 (sperm preparation), Pearl 2 (COC retrieval and oocyte denudation), and Pearl 3 (sperm selection, laser immobilization, and piezo-ICSI)—were used in various combinations. Multiple AIs were developed and deployed across these systems. This IRB-approved study was conducted at Hope IVF, Guadalajara, México. MAIN RESULTS AND THE ROLE OF CHANCE: The automated systems achieved 64.3% fertilization (45/70) and 42.2% usable blastocyst formation per zygote (19/45), compared to 81% (47/58) and 59.6% (28/47) with manual procedures. Transfers from the automated arm resulted in five live births, three biochemical pregnancies, and one early loss at 7 weeks. The live birth rate per transfer of a single warmed blastocyst in the automated arm was 5/12 (41.7%). LIMITATIONS, REASONS FOR CAUTION: The small sample size prevented statistical comparison between automated and manual procedures. Some steps required operator support via direct intervention or digital control. Autonomy (defined as automated execution without human intervention) was achieved only in sperm preparation and selected ICSI tasks. A larger study using an updated system is underway. WIDER IMPLICATIONS OF THE FINDINGS: This study demonstrates the feasibility of automating Day 0 IVF procedures, with the potential to improve standardization and reduce protocol drift, fatigue, and operator variability. Our findings support a phased integration of automation to meet growing ART demands. STUDY FUNDING/COMPETING INTEREST(S): The study was sponsored by Conceivable Life Sciences. A.C.-B. is an employee, shareholder, and company officer at Conceivable Life Sciences and also holds shares in IVF 2.0. G.M.-R. is a stock option holder at Conceivable Life Sciences and has received consulting fees from both Conceivable Life Sciences and IVF 2.0. A.F.-S.F. is an employee and stock option holder at Conceivable Life Sciences. N.C.-B. is a stock option holder at Conceivable Life Sciences and has received consulting fees from the company, and he is also an employee, shareholder, and company officer at Embryotools. A.M. is a shareholder and company officer at Conceivable Life Sciences and holds shares in TMRW Life Sciences. M.A. is a stock option holder at Conceivable Life Sciences and has received consulting fees and travel support from the company; she has also received consulting fees from TMRW Life Sciences. G.S. is an employee and stock option holder at Conceivable Life Sciences and has received consulting fees from IVF 2.0. C.M. is an employee and stock option holder at Conceivable Life Sciences. E.H.-M. is an employee and stock option holder at Conceivable Life Sciences. R.V.-M. is an employee and stock option holder at Conceivable Life Sciences and has received consulting fees from IVF 2.0. V.M. is an employee and stock option holder at Conceivable Life Sciences. E.M. is an employee of Embryotools. A.V.A. has no conflicts of interest to declare. V.O.-H. is an employee and stock option holder at Conceivable Life Sciences and has received consulting fees from IVF 2.0. F.A.-G. is an employee and stock option holder at Conceivable Life Sciences. A.Á.L. is an employee and stock option holder at Conceivable Life Sciences. M.A. is an employee of Embryotools. Q.M.-A. is an employee of Embryotools. J.G.E.F. is an employee and stock option holder at Conceivable Life Sciences. L.M.C.O. has no conflicts of interest to declare. C.P.B. is an employee and stock option holder at Conceivable Life Sciences. D.J.S.-G. has no conflicts of interest to declare. J.C. is an employee, shareholder, stock option holder, and company officer at Conceivable Life Sciences and holds shares in IVF 2.0, Althea Science, TMRW Life Sciences, Kindbody, and Reproductive Healthcare. Furthermore, A.C.-B., G.M.-R., A.F.-S.F., A.M., A.Á.L., and J.C. declare inventorship on US patent 12,349,940 B2 protecting automated oocyte denudation. A.C.-B., G.M.-R., A.F.-S.F., C.M., R.V.-M., V.O.-H., E.H.-M., V.M., A.M., and J.C. declare inventorship on US patent 12,245,793 B2 protecting robotic handling systems for IVF laboratories. A.C.-B., G.M.-R., A.F.-S.F., C.M., G.S., V.M., J.C., and A.M....


  • Top Cited Papers
    Open Access

    Artificial intelligence in assisted reproductive technology: separating the dream from reality

    by Jacques Cohen, Giuseppe Silvestri, Omar Paredes, Hector E. Martin-Alcala, Alejandro Chavez-Badiola, Mina Alikani, Giles A. Palmer


  • Open Access

    A digitally controlled, remotely operated ICSI system: case report of the first live birth

    by Gerardo Mendizabal-Ruiz, Alejandro Chavez-Badiola, Estefanía Hernández-Morales, Roberto Valencia-Murillo, Vladimir Ocegueda-Hernández, Nuno Costa-Borges, Enric Mestres, Mónica Acacio, Queralt Matia-Algué, Adolfo Flores-Saiffe Farías, et al.


  • Use and understanding of AI in the ART laboratory: an international survey

    by Giles Anthony Palmer, Omar Paredes, Andrew Drakeley, Alejandro Chavez-Badiola, Thomas E. Woolley, Katerina Kaouri, Jacques Cohen


  • The Internet of Things in assisted reproduction

    by Giles A. Palmer, Giles Tomkin, Héctor Emanuel Martín-Alcalá, Gerardo Mendizabal-Ruiz, Jacques Cohen


  • Open Access

    P-093 Single sperm morphokinetic variables during ICSI at the time of sperm aspiration into the microneedle

    by I Aguilar, A Chavez-Badiola, O Paredes, A Flores-Saiffe Farías, A J Drakeley, D Sakkas, O Ocali, M Hernández León, G Mendizabal Ruiz, A Valadez Aguilar, et al.

    Study question: Is it possible to classify sperm morphology as normal or abnormal based on their kinetic characteristics? Summary answer: Using different classifiers, it was found that balanced dataset the classification scores of individual sperm morphology can be optimized during their motility just before ICSI What is known already: Sperm selection plays a crucial role during ICSI. This selection by the embryologists is accompanied by two factors: motility parameters of the sperm to be injected, as well as the morphology. Motility affects morphological decision-making which may be subjective due to spermatozoa not being in a narrow vertical space in a PVP droplet, i.e. counting chamber. Machine/Deep Learning models -as classifiers- are gaining popularity in IVF as it could minimize subjectivity in gamete selection. SiD software is an algorithm that from a group of spermatozoa characteristics can support the selection of a single sperm during real time ICSI. Study design, size, duration: In this prospective study 1699 individual spermatozoa were video-recorded (resolution of 200 X 200 pix.) during sperm selection in a 7%PVP solution. Motility variables (VSL, VCL, LIN, VAP, ALH, WOB, STR, MAD) were obtained from each video using the software SiD. Each sperm was classified as normal or abnormal. Based on motility variables, different classification models were used to make a morphokinetic association of the variables with the classification of each sperm. Participants/materials, setting, methods: 1699 individual spermatozoa were classified and labeled by three senior embryologists into two categories: normal or anormal. To belong to any category, at least two embryologists had to agree. A normalization was applied to the motility data obtained with SiD. Machine learning classification models were applied. The three classification models with the best results were selected to optimize the hyper-parameters and improve their performance. Main results and the role of chance: A set of motility variables were obtained using the software SiD1 (IVF2.0 Ltd., UK) these were used as features for each of the sperm samples and were tagged either as normal or abnormal having a total of 257 normal samples and 1442 abnormal samples. Different classification algorithms were used to perform sperm classification as normal and abnormal. Then hyperparameter tuning algorithms such as GridSearch were used to compute the optimum values, finding KNN algorithm to achieve the best results to classify normal and abnormal spermatozoa with 80% accuracy. Given the nature of the unbalanced dataset, the F1 score was calculated, achieving 0.77, other algorithms such as Decision-Tree and Random-Forest were used achieving similar results in the F1 score. We will continue growing the dataset until it is balanced and run the same algorithms expecting the performance to improve. Limitations, reasons for caution: Each clinic's laboratory setup, including the camera used to record the ICSI procedure, is a clinic-specific configuration. Sperm abnormality detection is sensitive to camera resolution, showing the classifiers are resolution-dependent observers. To replicate these results, it is important to consider the quality of the camera. Wider implications of the findings: Using the selected kinematics features, it is possible to classify individual spermatozoa during motility as having normal or abnormal morphology. Results may improve using standard morphological examination of each population and having more normal sperm samples. Trial registration number: Not applicable

  • The in vitro fertilization laboratory: teamwork and teaming

    by Alison Campbell, Jacques Cohen, Kristen Ivani, Dean Morbeck, Giles Palmer, Sharon Mortimer


  • Setting Up an ART Unit: Planning, Design, and Construction

    by Jacques Cohen, Mina Alikani, Antonia Gilligan, Tim Schimmel